International Research Journal of Engineering and Technology (IRJET) e-ISSN: 2395-0056
Volume: 10 Special Issue: | Apr 2023 www.irjet.net p-ISSN: 2395-0072

International Conference on Recent Trends in Engineering & Technology- 2023 (ICRTET-3)
Organised by: VSM College of Engineering, Ramachandrapuram

ADVANCED MACHINE LEARNING APPROACHES FOR ACCURATE PREDICTION OF DRUG-DRUG INTERACTIONS IN CLINICAL PRACTICE

K. SUREKHA[1], P. SRINIVAS REDDY[2], A. S. R. PRASAD[3], S. V. D. TARUN[4], K. SURESH[5], P. RAMYA SAI SRI[6]

[1.]Associate Professor, [2-6.] Students B.Tech. Computer Science Engineering, V.S.M. College Of Engineering, Ramachandrapuram, A.P, India

---

ABSTRACT:

The pharmacological effect of a drug is influenced by another drug, which usually appears when two or more drugs are administered simultaneously for a patient. These associations are also defined as drug-drug interactions (DDIs), and are either favourable efficacy or undesirable DDIs according to clinical results. Positive DDIs can provide more effective treatments and reduce the suffering of patients. However, undesirable DDIs are the major cause of adverse reaction events. In serious cases, they can result in the drug withdrawalfrom the drug market and the death of a patient who is treated with multi-drugs. Currently, multi-drug therapies have been widely used in treating multiple illnesses or complex diseases, such as cancer. The original purpose of multi-drugs treatment is to alleviate the patient suffering, improve the treatment effect and increase the overall survival rate. However, undesirable DDIs have also been developed along with more and more drugs used in the synergistic treatment, and which also influence the treatment effect and even lead to serious complications as well as the financial burden. Therefore, in order to reduce the cost of drug development and improve the treatment effect, it is very urgent to identify DDIs in the drug development process.

1. INTRODUCTION

The pharmacological effect of a drug is influenced by another drug, which usually appears when two or more drugs are administered simultaneously for a patient. These associations are also defined as drug-drug interactions (DDIs), and are either favorable efficacy or undesirable DDIs according to clinical results. Positive DDIs can provide more effective treatments and reduce the suffering of patients. However, undesirable DDIs are the major cause of adverse reaction events . In serious cases, they can result in the drug withdrawalfrom the drug market and the death of a patient who is treated with multi-drugs . Currently, multi-drug therapies have been widely used in treating multiple illnesses or complex diseases, such as cancer The original purpose of multi-drugs treatment is to alleviate the patient suffering, improve the treatment effect and increase the overall survival rate. However, undesirable DDIs have also been developed along with more and more drugs used in the synergistic treatment, and which also influence the treatment effect and even lead to serious complications as well as the financial burden. Recently, many studies have proven that some commonly used drugs have high possibility to interact with each other, such as lipid lowering drugs, macrolides, oral antifungal agents, which are widely used to synergistic treatments. Previous studies about DDIs can be divided into three categories: pharmaceutic, pharmacokinetic (PK) and pharmacodynamic (PD). The pharmaceutic DDIs usually result from multi-drugs with the chemical incompatibility. A PK interaction is defined as the effects of a drug in the absorbed, distributed, or metabolized process of another drug in the patient body, which is usually related to adverse responses. PD interactions often result from different drugs acting on the same receptor, site, or physiological system, and could have also either synergistic or harmful effects for patients . Many PK and PD interactions have been used for inferring DDIs in previous studies.

In silico, in vitro and in vivo experiments are the methods to discover DDIs among drugs, and the two latter methods are usually very time-consuming and labor-intensive cycles. In addition, the side effects caused by DDIs are hard to be measured in vitro or in vivo experiments, which makes results that these methods hard to be executed. As more and more patients are simultaneously treated by multi-drugs, identifying DDIs has become an important issue of bioinformatics research and a very urgent need to drug developments. Moreover, compared to traditional biomedical experiment methods, the computational methods provide an opportunity to predict new DDIs with the low cost and high accuracy. Therefore, by considering its advancement to biological experiments, there exists a high demand for predicting DDIs via computational approaches. In addition, the development of medical technologies and applications of multi-drug treatments also further imposes a very urgent

demand to develop computational methods to predict potential DDIs.

2. EXISTING SYSTEM

The well known experiments for obtaining drug to drug interactions are VIVO, VITRO. In silico, vitro and vivo experiments, we will discover DDIs among drugs, and the twolatter methods are usually very time-consuming and labor- intensive cycles. In addition, the side effects caused by DDIs are hard to be measured in vitro or in vivo experiments, which makes results that these methods hard to be executed. As more and more patients are simultaneously treated by multi- drugs, identifying DDIs has become an important issue ofbioinformatics research and a very urgent need to drug developments.

Disadvantages

These methods to discover DDIs among drugs, are usually very time-consuming. The side effects caused by DDIs are hard to be measured in vitro or in vivo experiments, which makes results that these methods hard to be executed..

3. PROPOSED SYSTEM

The proposed system aims to predict drug-drug interactions (DDIs) using integrated similarity and supervised learning techniques. The system is designed to address the growing need for accurate and efficient methods for predicting DDIs, which can help improve patient safety and avoid adverse drugreactions.

The system consists of several modules that work together to achieve the goal of predicting DDIs. The first module is responsible for collecting and pre-processing the data. This includes gathering information about the drugs, their chemical properties, and their known interactions from various sources,such as drug databases and scientific literature. The data is then cleaned, normalized, and transformed into a format suitable for further analysis.

The next module is the similarity module, which calculates thesimilarity between pairs of drugs based on their chemical properties, such as molecular structure, physicochemical properties, and pharmacological effects. This module uses various similarity measures, such as Tanimoto coefficient and Euclidean distance, to compute the similarity scores.

The supervised learning module is then used to train the classification models using the pre-processed data and similarity scores. We have used five classification ML algorithms, namely logistic regression, decision tree, random forest, k-nearest neighbour, and support vector machine, to predict DDIs. These algorithms are selected based on their performance in previous studies and their ability to handle high-dimensional and complex data.

The system is evaluated using various metrics, such as accuracy, precision, recall, and F1-score, to measure the performance of the classification models. The evaluation is done on both the training and testing data to ensure the robustness and generalization of the models.

The proposed system can provide valuable insights into potential DDIs and help healthcare professionals make informed decisions about drug prescriptions. The system can also be integrated into electronic health records and drug databases to provide real-time alerts and warnings about potential DDIs.

Advantages

1. Improved patient safety: The system can help identify potential drug-drug interactions, which can lead to adverse drug reactions. By avoiding these interactions, patient safety can be improved, and the risk of harmful side effects can be reduced.

2. Efficiency: The system can process large amounts of data quickly and accurately, making it a valuable tool for healthcare professionals who need to make quick decisions about drug prescriptions.

3. Increased accuracy: By combining similarity measures and supervised learning techniques, the system can provide more accurate predictions of drug-drug interactions than traditionalmethods.

4. Scalability: The system can be easily scaled to handle new drugs and interactions as they become available, making it a flexible and adaptable tool for predicting drug-drug interactions.

5. Cost-effectiveness: The system can potentially reduce healthcare costs by preventing adverse drug reactions and avoiding unnecessary medical treatments.

4. SYSTEM ARCHITECTURE:



5. MODULES IMPLEMENTATION

Service Provider

In this module, the Service Provider has to login by using valid username and password. After login successful he can do some operations such as Login, Train and Test Drugs Data Sets, ViewDrugs Trained and Tested Accuracy in Bar Chart, View Drugs Trained and Tested Accuracy Results, View Drug to Drug Interaction Predicted Details, Find Drug to Drug Interaction Predicted Ratio, Download Drug to Drug Interaction, View Drug to Drug Interaction Predicted Ratio Results, View AllRemote Users.

View and Authorize Users

In this module, the admin can view the list of users who all registered. In this, the admin can view the user's details such as, username, email, address and admin authorizes the users.

Remote User

In this module, there are n numbers of users are present. User should register before doing any operations. Once user registers, their details will be stored to the database. After registration successful, he has to login by using authorized user name and password. Once Login is successful user will do some operations like Register & Login, Predict Drug to Drug Interaction Type, View your Profile.

6. CONCLUSION

Multi-drug therapies have widely been used to treat diseases, especially complex diseases such as cancer to improve the treatment effect and reduce the burden of patients. However,the adverse effects resulted from multi-drug therapies have also been observed, which may caused some serious complications and even the patient death. Therefore, identifying drug-drug interactions is helpful in contributing to improved treatment of diseases and reducing the difficulty of drug developments. Especially, it is very necessary to develop new computational methods for identifying DDIs.

In this study, we propose a new computational method (DDI- IS SL) to infer DDIs. DDI-IS-SL integrates the drug chemical, drug biological and drug phenotypic data. The used chemical substructure information of drugs is Pub-Chem substructure which is the 2D binary fingerprints (0 and 1). The biological features of drugs contain drug target interactions, drug enzymes, drug transports and drug pathways. The phenotypicdata of drugs include drug indications, drug side effects and drug-off side effects. For each drug, a high-dimensional binary feature vector is constructed with these data. Then we calculate the feature similarity of drugs with the cosine measure. We also compute the GIP similarity of drugs by known DDIs. The final similarity of drugs is calculated as the mean of drug feature similarity and drug GIP similarity. Then we use a semi-supervised learning model (RLS) to compute the probability scores of drug pairs. In the 5-fold cross validation and 10-fold cross validation, DDI-IS-SL achieves the betterprediction performance than other competing methods.

Furthermore, for new drugs, we also calculate the relational initial interaction scores by using the node-based drug network diffusion method. Our method also achieves the better prediction performance in de novo validation than competing methods.

Future Enhancement

Although the DDI-IS SL is an effective approach to predict the potential DDIs, there are still some areas for the improvement. For example, we can also consider other more sophisticated methods to integrate the chemical, biological and phenotypic data of drugs. In addition, other prediction models such as deep learning method and matrix approximation method [68], [69], [70] also should be tried to identify DDIs in the future

7. REFERENCES

1. D. Quinn and R. Day, "Drug interactions of clinical importance," Drug safety, vol. 12, no. 6, pp. 393–452, 1995.

2. T. Prueksaritanont, X. Chu, C. Gibson, D. Cui, K. L. Yee, J. Ballard,T. Cabalu, and J.Hochman, "Drug–drug interaction studies: Regulatory guidance and an industry perspective," The AAPS journal,m vol. 15, no. 3, pp. 629–645, 2013.

3. H. Kusuhara, "How far should we go? perspective of drug- drug interaction studies in drug development," Drug metabolism and pharmacokinetics, vol. 29, no. 3, pp. 227– 228, 2014.

4. N. R. Crowther, A. M. Holbrook, R. Kenwright, and M. Kenwright, "Drug interactions among commonly used medications. Chart simplifies data from critical literature review." Canadian Family Physician, vol. 43, p. 1972, 1997.

5. R. Nahta, M.-C. Hung, and F. J. Esteva, "The her-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells," Cancer research, vol .64, no. 7, pp. 2343–2346, 2004.

6. T.-C. Chou, "Drug combination studies and their synergy quantification using the chou-talalay method," Cancer research, vol. 70, no. 2, pp. 440–446, 2010.

7. K. Venkata Krishnan, L. L. von Moltke, R. Obach, and D. J. Greenblatt, "Drug metabolism and drug interactions: application and clinical value of in vitro models," Current drug metabolism, vol. 4, no. 5, pp. 423–459, 2003.

8. P. J. Neuvonen, M. Niemi, and J. T. Backman, "Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance," Clinical Pharmacology & Therapeutics, vol. 80, no. 6, pp. 565–581, 2006.

9. Y. B¨ ottiger, K. Laine, M. L. Andersson, T. Korhonen, B. Molin, M.-L. Ovesj¨ o, T. Tirkkonen, A. Rane, L. L. Gustafsson, and B. Eiermann, "Sfinxła drug-drug interaction database designed for clinical decision support systems," European journal of clinical pharmacology, vol. 65, no. 6, pp. 627–633, 2009.

10. M. P. Pai, D. M. Graci, and G. W. Amsden, "Macrolide drug interactions: an update," Annals of Pharmacotherapy,vol. 34, no. 4, pp. 495–513, 2000.

11. J. Kuhlmann andW.M¨ uck, "Clinical-pharmacological strategies to assess drug interaction potential during drugdevelopment," Drug safety, vol. 24, no. 10, pp. 715–725, 2001.

12. S. Preskorn and S. Werder, "Detrimental antidepressant drug– drug interactions: Are they clinically relevant?" Neuropsychopharmacology, vol. 31, no. 8, pp. 1605–1612, 2006.

13. D. Sridhar, S. Fakhraei, and L. Getoor, "A probabilistic approach for collective similarity-based drug–drug interaction prediction," Bioinformatics, vol. 32, no. 20, pp. 3175–3182, 2016.

14. S. Ekins and S. A. Wrighton, "Application of in silico approaches to predicting drug–drug interactions," Journal of pharmacological and toxicological methods, vol. 45, no. 1, pp.65–69, 2001.

15. G. Jin, H. Zhao, X. Zhou, and S. T. Wong, "An enhanced petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data," Bioinformatics, vol. 27, no. 13, pp. i310–i316, 2011.

BIOGRAPHIES

Team Guide, K. Surekha is working as associate professor in CSE department VSM College of Engineering, Ramachandrapuram.

Team Leader, P. Srinivas Reddy is B. Tech Student of CSE department, VSM College of Engineering, Ramachandrapuram

Team Member, K. Suresh is B.Tech Student of CSE department, VSM College of Engineering, Ramachandrapuram

Team Member, A. S. R. Prasad is B.Tech Student of CSE department, VSM College of Engineering, Ramachandrapuram

Team Member S. V. D. Tarun is B.Tech Student of CSE department, VSM College of Engineering, Ramachandrapuram

Team Member P. Ramya Sai Sri is B.Tech Student of CSE department, VSM College of Engineering, Ramachandrapuram